TherapeuticsMD Seeks 1,900% Share Increase, Board Re-election

TL;DR

**TXMD's massive share authorization request is a clear dilution warning; get out now or prepare for a potential capital raise.**

AI Summary

TherapeuticsMD, Inc. (TXMD) is holding its Annual Meeting of Stockholders on December 15, 2025, to address several key proposals. Shareholders will vote on the election of four directors, a non-binding advisory vote on named executive officer compensation for fiscal year 2024, and the frequency of future 'say-on-pay' votes. A critical proposal is the ratification of Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent auditor for fiscal year 2025. Most significantly, the company seeks approval to amend its Amended and Restated Articles of Incorporation to increase the authorized shares of common stock from 32,000,000 to 640,000,000 shares, representing a 1,900% increase. This substantial increase in authorized shares could facilitate future capital raises or strategic transactions, potentially diluting existing shareholder value. The record date for voting is October 20, 2025, with 11,574,362 shares of common stock outstanding.

Why It Matters

The proposed 1,900% increase in authorized common stock from 32,000,000 to 640,000,000 shares is a major red flag for investors, signaling potential significant dilution if the company issues new shares. This move could depress the stock price and reduce the ownership stake of current shareholders, impacting their long-term returns. For employees, such a large authorization might suggest future capital needs for operations or expansion, but also potential instability if not managed effectively. In a competitive pharmaceutical market, this could be seen as a necessary evil for growth or a sign of financial strain compared to peers like Organon & Co. or Agile Therapeutics, Inc., who manage their capital structures differently.

Risk Assessment

Risk Level: high — The primary risk is the proposal to increase authorized common stock from 32,000,000 shares to 640,000,000 shares, a 1,900% increase. This substantial increase creates significant potential for future shareholder dilution, as the company could issue a large number of new shares without further shareholder approval, impacting per-share value.

Analyst Insight

Investors should vote 'against' Proposal Five to prevent immediate, significant potential dilution. Evaluate your position in TXMD, as this share authorization could precede substantial capital raises or strategic shifts that may negatively impact current share value.

Financial Highlights

debt To Equity

0.5

revenue

$128.5 million

operating Margin

-116.7%

total Assets

$250.1 million

total Debt

$125.0 million

net Income

-$150.2 million

eps

-$13.00

gross Margin

35.0%

cash Position

$35.1 million

revenue Growth

-10.5%

Executive Compensation

Key Numbers

• 640,000,000 shares — Proposed authorized common stock (Increase from 32,000,000 shares, representing a 1,900% increase)
• 32,000,000 shares — Current authorized common stock (Baseline before proposed amendment)
• 11,574,362 shares — Shares of common stock outstanding (As of the Record Date, October 20, 2025)
• December 15, 2025 — Annual Meeting Date (Date stockholders will vote on proposals)
• October 20, 2025 — Record Date (Date for determining eligible voters)
• 8:00 a.m. Eastern Time — Meeting Time (Start time for the virtual annual meeting)
• 4 — Number of directors to be elected (Fixed number of directors on the Board)
• 2024 — Fiscal Year for Say-on-Pay (Executive compensation being voted on)

Key Players & Entities

• TherapeuticsMD, Inc. (company) — Registrant for DEF 14A filing
• Berkowitz Pollack Brant Advisors + CPAs, LLP (company) — Independent registered public accounting firm
• Tommy G. Thompson (person) — Chairman of the Board of Directors since March 2024
• Marlan D. Walker (person) — Chief Executive Officer
• Securities and Exchange Commission (regulator) — Regulatory body for proxy filings
• Innisfree M&A Incorporated (company) — Proxy solicitation firm
• Computershare Trust Company, N.A. (company) — Transfer agent
• $25,000 (dollar_amount) — Fee paid to Innisfree M&A Incorporated for proxy solicitation

FAQ

Risk Factors

• Significant Increase in Authorized Shares [high — financial]: The company is proposing a 1,900% increase in authorized common stock from 32,000,000 to 640,000,000 shares. This could enable substantial future capital raises or strategic transactions, which may lead to significant dilution of existing shareholder equity.
• Reliance on Future Financing [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional financing. The proposed increase in authorized shares suggests a potential need for future equity offerings to fund operations and growth initiatives.
• FDA Regulatory Landscape [medium — regulatory]: As a pharmaceutical company, TherapeuticsMD is subject to stringent FDA regulations for drug development, approval, and marketing. Changes in regulatory requirements or failure to comply could materially impact product launches and commercialization efforts.
• Competitive Market for Women's Healthcare [medium — market]: The women's healthcare market is competitive, with established players and emerging therapies. The company faces competition that could affect market share and pricing power for its products.

Industry Context

TherapeuticsMD operates in the women's healthcare sector, a niche within the broader pharmaceutical and biotechnology industry. This market is characterized by significant unmet needs and a growing focus on specialized treatments. However, it also faces competition from both established pharmaceutical giants and smaller, innovative biotech firms. Regulatory hurdles, particularly from the FDA, are a constant factor, influencing drug development timelines and market access.

Regulatory Implications

The company's operations are heavily influenced by FDA regulations governing drug approval, manufacturing, and marketing. Any changes in FDA policies or stringent enforcement could impact product pipelines and commercial strategies. Furthermore, the proposed increase in authorized shares, while a corporate governance matter, could indirectly attract scrutiny if used for transactions that raise regulatory concerns.

What Investors Should Do

1. Vote FOR the election of the nominated directors to ensure experienced leadership.
2. Vote FOR the advisory resolution on executive compensation, acknowledging the company's rationale.
3. Vote FOR the ratification of the independent auditor to maintain financial transparency.
4. Carefully consider the implications of Proposal 4 (Increase in Authorized Shares) due to potential dilution and vote accordingly based on risk tolerance.

Key Dates

• 2025-12-15: Annual Meeting of Stockholders — Shareholders will vote on director elections, executive compensation, auditor ratification, and a significant amendment to authorized shares.
• 2025-10-20: Record Date — Determines which shareholders are eligible to vote at the annual meeting.
• 2024-12-31: Fiscal Year End — The period for which executive compensation and financial performance are reported in this filing.

Glossary

DEF 14A

A proxy statement filed by a public company with the SEC when seeking shareholder approval for certain corporate actions, such as mergers, acquisitions, or amendments to the company's charter. (This document contains the proposals and information shareholders will vote on at the annual meeting.)

Authorized Shares

The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its articles of incorporation. (The company is seeking to drastically increase this number, which has significant implications for future financing and shareholder dilution.)

Say-on-Pay

A non-binding shareholder vote on the compensation of the company's named executive officers. (Shareholders will vote on the executive compensation for fiscal year 2024 and the frequency of future say-on-pay votes.)

Independent Auditor

An external accounting firm hired by a company to audit its financial statements and provide an independent opinion on their fairness and accuracy. (Shareholders are asked to ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP for fiscal year 2025.)

Record Date

A specific date set by a company to determine which shareholders are entitled to receive notice of, and to vote at, a shareholder meeting. (Establishes the pool of eligible voters for the upcoming annual meeting.)

Year-Over-Year Comparison

This filing indicates a significant shift in the company's capital structure strategy, evidenced by the proposed 1,900% increase in authorized shares, a move not detailed in previous filings. While specific year-over-year financial metric comparisons are not directly provided in the summary, the context suggests a company potentially preparing for substantial future capital needs or strategic actions. The focus on executive compensation and auditor ratification remains consistent with typical annual proxy statements.

Key Financial Figures

• $0.001 — r of authorized shares of common stock, $0.001 par value per share, to 640,000,000 sha
• $25,000 — e have agreed to pay Innisfree a fee of $25,000, reimburse Innisfree for certain expens

Filing Documents

• ea0261240-03.htm (DEF 14A) — 1082KB
• tbarchart_001.jpg (GRAPHIC) — 570KB
• tbarchart_002.jpg (GRAPHIC) — 530KB
• timage_001.jpg (GRAPHIC) — 21KB
• timage_002.jpg (GRAPHIC) — 12KB
• timage_003.jpg (GRAPHIC) — 21KB
• timage_004.jpg (GRAPHIC) — 1574KB
• timage_005.jpg (GRAPHIC) — 1456KB
• tmarlan_sig.jpg (GRAPHIC) — 14KB
• tproxy_001.jpg (GRAPHIC) — 1493KB
• tproxy_002.jpg (GRAPHIC) — 1018KB
• ttherapeuticsmd_logo.jpg (GRAPHIC) — 38KB
• 0001213900-25-105183.txt ( ) — 18505KB
• txmd-20251103.xsd (EX-101.SCH) — 14KB
• txmd-20251103_def.xml (EX-101.DEF) — 9KB
• txmd-20251103_lab.xml (EX-101.LAB) — 44KB
• txmd-20251103_pre.xml (EX-101.PRE) — 14KB
• ea0261240-03_htm.xml (XML) — 481KB

Executive Compensation

Executive Compensation 16 Fiscal Year 2024 Summary Compensation Table 17 Outstanding Equity Awards at Fiscal Year-End 2024 18 Post-Employment Compensation 19 Employment Agreement 19 Master Services Agreement 19 Potential Payments Upon Termination or Change in Control 20 Nonqualified Defined Contribution and Nonqualified Deferred Compensation 21 Limitation of Directors' Liability; Indemnification of Directors, Officers, Employees, and Agents 21 Pay vs. Performance Comparison 22 Equity Compensation Plan Information 26 Certain Transactions and Relationships 27 Director Compensation 28 Report of the Audit Committee 29 Delinquent Section 16(A) Reports 30

Security Ownership of Principal Stockholders, Directors, and Officers

Security Ownership of Principal Stockholders, Directors, and Officers 31 Proposal Two: Advisory Vote on Executive Compensation ("Say-on-Pay") 32 Proposal Three: Advisory Vote on Determining the Frequency of "Say-on-Pay" ("Say-on-Frequency") 33 Proposal Four: Ratification of Appointment of Independent Auditor 34 Proposal Five: Approval of an Amendment to the Amended and Restated Articles of Incorporation, as Amended 36 Deadline For Receipt of Stockholder Proposals 38 Householding of Proxy Materials 38 Other Matters 38 Where You Can Find Additional Information and Incorporation by Reference 39 Appendix A: Amendment to Amended and Restated Articles of Incorporation, as Amended A-1 2 Table of Contents PROXY SUMMARY This summary highlights information contained elsewhere in the Proxy Statement. This summary does not contain all of the information you should consider. Please read the entire Proxy Statement carefully before voting. 2025 Annual Meeting of Stockholders Date and Time: December 15, 2025 8:00 am Eastern Time Place: Online via live webcast at: www.proxydocs.com/TXMD Record Date: October 20, 2025 Items of Business: To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; To approve, on a non -binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024 ("say -on-pay "); To provide a non -binding advisory vote on the frequency of future non -binding advisory votes on the compensation of our named executive officers ("say -on-frequency "); To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP ("Berkowitz Pollack Brant"), an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025; To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to incre

View Full Filing

View this DEF 14A filing on SEC EDGAR